Skip to main content

Table 4 Results of uni- and multivariate analyses for androgen deprivation therapy-free survival (ADT-FS)

From: Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

  Univariate analysis Multivariable analysis
p value p value OR, (95% CI)
Initial T stage (≤T2 vs ≥ T3) 0.07   
Initial N stage (N0 vs N1) 0.95   
Initial PSA level in ng/ml (≤20 vs > 20) 0.26   
PSA nadir after RP (≤0.07 ng/mL vs > 0,07 ng/mL) 0.05 0.20 2.02 (0.68–5.99)
Number of removed LN at RP (≤15 vs > 15) 0.31   
Initial risk group (intermediate+high risk vs. very high risk) 0.02 0.10 2.58 (0.8–7.98)
PSA dt (≤6 months, > 6 months) 0.10   
Radiotherapy type (CF-RT vs., SBRT) 0.73   
No. of irradiated metastases (1 vs > 1) 0.51   
Type of metastases (Lymph node vs bone) 0.12   
RT dose (≤50 Gy vs > 50 Gy) 0.44   
  1. ADT androgen deprivation therapy, CF-RT conventionally fractionated radiotherapy type, dt doubling time, Gy Gray, LN lymph nodes, PSA prostate-specific antigen, RP radical prostatectomy, sRT salvage radiotherapy, SBRT stereotactic body radiation therapy, SIB simultaneous integrated boost